<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ebronucimab (AK102) - PCSK9 Monoclonal Antibody</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }
        
        :root {
            --primary: #0066CC;
            --primary-light: #E8F2FF;
            --success: #00A86B;
            --warning: #F39C12;
            --danger: #E74C3C;
            --text-primary: #2C3E50;
            --text-secondary: #7F8C8D;
            --border: #E1E8ED;
            --background: #FFFFFF;
            --background-alt: #F8FAFB;
            --shadow-sm: 0 1px 3px rgba(0,0,0,0.08);
            --shadow-md: 0 4px 6px rgba(0,0,0,0.1);
            --shadow-lg: 0 10px 25px rgba(0,0,0,0.1);
        }
        
        body {
            font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Inter', Roboto, sans-serif;
            background: var(--background-alt);
            color: var(--text-primary);
            line-height: 1.6;
            font-size: 14px;
        }
        
        /* Header */
        .header {
            background: white;
            border-bottom: 1px solid var(--border);
            padding: 16px 24px;
            position: sticky;
            top: 0;
            z-index: 100;
            box-shadow: var(--shadow-sm);
        }
        
        .header-content {
            max-width: 1400px;
            margin: 0 auto;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }
        
        .back-button {
            display: inline-flex;
            align-items: center;
            gap: 8px;
            padding: 8px 16px;
            background: var(--background-alt);
            border: 1px solid var(--border);
            border-radius: 6px;
            color: var(--text-primary);
            text-decoration: none;
            font-size: 14px;
            transition: all 0.2s;
        }
        
        .back-button:hover {
            background: var(--primary-light);
            border-color: var(--primary);
            color: var(--primary);
        }
        
        .status-badge {
            padding: 8px 16px;
            background: #E6F7ED;
            color: var(--success);
            border: 1px solid var(--success);
            border-radius: 20px;
            font-weight: 600;
            font-size: 12px;
        }
        
        /* Container */
        .container {
            max-width: 1400px;
            margin: 0 auto;
            padding: 24px;
        }
        
        /* Hero Section */
        .hero-section {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 32px;
            margin-bottom: 24px;
            box-shadow: var(--shadow-sm);
        }
        
        .drug-title {
            margin-bottom: 24px;
        }
        
        .drug-name {
            font-size: 32px;
            font-weight: 700;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .drug-company {
            font-size: 16px;
            color: var(--text-secondary);
            margin-bottom: 12px;
        }
        
        .drug-mechanism {
            display: inline-block;
            padding: 6px 16px;
            background: var(--primary-light);
            color: var(--primary);
            border-radius: 20px;
            font-size: 14px;
            font-weight: 500;
        }
        
        /* Quick Stats Grid */
        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
            gap: 16px;
            margin-bottom: 24px;
        }
        
        .stat-card {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 16px;
            box-shadow: var(--shadow-sm);
        }
        
        .stat-value {
            font-size: 24px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 4px;
        }
        
        .stat-label {
            font-size: 12px;
            color: var(--text-secondary);
            text-transform: uppercase;
            letter-spacing: 0.5px;
        }
        
        /* Navigation Tabs */
        .nav-tabs {
            display: flex;
            gap: 8px;
            margin-bottom: 24px;
            background: white;
            padding: 8px;
            border-radius: 8px;
            border: 1px solid var(--border);
        }
        
        .nav-tab {
            padding: 10px 20px;
            background: transparent;
            border: none;
            border-radius: 6px;
            color: var(--text-secondary);
            cursor: pointer;
            transition: all 0.2s;
            font-size: 14px;
            font-weight: 500;
        }
        
        .nav-tab:hover {
            background: var(--background-alt);
            color: var(--text-primary);
        }
        
        .nav-tab.active {
            background: var(--primary-light);
            color: var(--primary);
        }
        
        /* Tab Content */
        .tab-content {
            display: none;
        }
        
        .tab-content.active {
            display: block;
        }
        
        /* Section Styles */
        .section {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 24px;
            margin-bottom: 24px;
            box-shadow: var(--shadow-sm);
        }
        
        .section-header {
            font-size: 18px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 20px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }
        
        /* Info Cards */
        .info-card {
            background: var(--background-alt);
            border-left: 4px solid var(--primary);
            padding: 16px;
            border-radius: 4px;
            margin-bottom: 16px;
        }
        
        .info-card h3 {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .info-card p,
        .info-card ul {
            font-size: 13px;
            color: var(--text-secondary);
            line-height: 1.6;
        }
        
        .info-card ul {
            margin-left: 20px;
            margin-top: 8px;
        }
        
        /* Dosing Cards */
        .dosing-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(250px, 1fr));
            gap: 16px;
            margin-top: 16px;
        }
        
        .dosing-card {
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 20px;
            text-align: center;
            transition: all 0.2s;
        }
        
        .dosing-card:hover {
            box-shadow: var(--shadow-md);
            border-color: var(--primary);
        }
        
        .dosing-card.featured {
            border: 2px solid var(--primary);
            background: var(--primary-light);
        }
        
        .dosing-frequency {
            font-size: 28px;
            font-weight: 700;
            color: var(--primary);
            margin-bottom: 8px;
        }
        
        .dosing-details {
            font-size: 13px;
            color: var(--text-secondary);
            line-height: 1.6;
        }
        
        .dosing-details strong {
            color: var(--text-primary);
            display: block;
            margin-bottom: 4px;
        }
        
        /* Timeline */
        .timeline {
            position: relative;
            padding: 20px 0;
        }
        
        .timeline-line {
            position: absolute;
            left: 12px;
            top: 0;
            bottom: 0;
            width: 2px;
            background: var(--border);
        }
        
        .timeline-item {
            position: relative;
            padding-left: 40px;
            margin-bottom: 24px;
        }
        
        .timeline-dot {
            position: absolute;
            left: 4px;
            top: 4px;
            width: 18px;
            height: 18px;
            background: white;
            border: 3px solid var(--primary);
            border-radius: 50%;
        }
        
        .timeline-item.complete .timeline-dot {
            background: var(--primary);
        }
        
        .timeline-content {
            background: var(--background-alt);
            padding: 12px 16px;
            border-radius: 6px;
            border: 1px solid var(--border);
        }
        
        .timeline-date {
            font-size: 12px;
            font-weight: 600;
            color: var(--primary);
            margin-bottom: 4px;
        }
        
        .timeline-title {
            font-size: 14px;
            color: var(--text-primary);
            font-weight: 500;
        }
        
        .timeline-description {
            font-size: 12px;
            color: var(--text-secondary);
            margin-top: 4px;
        }
        
        /* Data Tables */
        .data-table {
            width: 100%;
            background: white;
            border: 1px solid var(--border);
            border-radius: 8px;
            overflow: hidden;
            box-shadow: var(--shadow-sm);
        }
        
        .data-table thead {
            background: var(--background-alt);
        }
        
        .data-table th {
            padding: 12px 16px;
            text-align: left;
            font-size: 12px;
            font-weight: 600;
            color: var(--text-secondary);
            text-transform: uppercase;
            letter-spacing: 0.5px;
            border-bottom: 2px solid var(--border);
        }
        
        .data-table td {
            padding: 12px 16px;
            font-size: 13px;
            color: var(--text-primary);
            border-bottom: 1px solid var(--border);
        }
        
        .data-table tbody tr:hover {
            background: var(--background-alt);
        }
        
        .data-table tbody tr:last-child td {
            border-bottom: none;
        }
        
        /* Efficacy Chart */
        .efficacy-chart {
            background: var(--background-alt);
            padding: 20px;
            border-radius: 8px;
            margin-top: 16px;
        }
        
        .chart-container {
            display: flex;
            align-items: flex-end;
            justify-content: space-around;
            height: 200px;
            margin-top: 20px;
        }
        
        .chart-bar-wrapper {
            display: flex;
            flex-direction: column;
            align-items: center;
            flex: 1;
        }
        
        .chart-value {
            font-size: 14px;
            font-weight: 600;
            color: var(--text-primary);
            margin-bottom: 8px;
        }
        
        .chart-bar {
            width: 60px;
            background: var(--primary);
            border-radius: 4px 4px 0 0;
            transition: all 0.3s;
            position: relative;
        }
        
        .chart-bar:hover {
            opacity: 0.8;
        }
        
        .chart-bar.secondary {
            background: var(--text-secondary);
        }
        
        .chart-bar.success {
            background: var(--success);
        }
        
        .chart-label {
            font-size: 11px;
            color: var(--text-secondary);
            text-align: center;
            margin-top: 8px;
        }
        
        /* Safety Grid */
        .safety-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(180px, 1fr));
            gap: 12px;
            margin-top: 16px;
        }
        
        .safety-item {
            background: white;
            border: 1px solid var(--border);
            border-radius: 6px;
            padding: 12px;
            text-align: center;
        }
        
        .safety-value {
            font-size: 20px;
            font-weight: 600;
            color: var(--success);
            margin-bottom: 4px;
        }
        
        .safety-label {
            font-size: 11px;
            color: var(--text-secondary);
        }
        
        /* Alert Boxes */
        .alert {
            padding: 12px 16px;
            border-radius: 6px;
            margin: 16px 0;
            display: flex;
            align-items: flex-start;
            gap: 12px;
        }
        
        .alert-warning {
            background: #FFF4E6;
            border: 1px solid var(--warning);
            color: #856404;
        }
        
        .alert-info {
            background: var(--primary-light);
            border: 1px solid var(--primary);
            color: var(--primary);
        }
        
        .alert-icon {
            font-size: 16px;
        }
        
        .alert-content {
            flex: 1;
            font-size: 13px;
            line-height: 1.5;
        }
        
        /* Badge */
        .badge {
            display: inline-block;
            padding: 2px 8px;
            border-radius: 12px;
            font-size: 11px;
            font-weight: 600;
            margin-left: 8px;
        }
        
        .badge-warning {
            background: #FFF4E6;
            color: var(--warning);
        }
        
        .badge-success {
            background: #E6F7ED;
            color: var(--success);
        }
        
        /* Progress Bars */
        .progress-bar {
            background: var(--border);
            height: 8px;
            border-radius: 4px;
            overflow: hidden;
            margin: 8px 0;
        }
        
        .progress-fill {
            height: 100%;
            background: var(--primary);
            transition: width 0.5s ease;
        }
        
        /* Responsive */
        @media (max-width: 768px) {
            .container {
                padding: 16px;
            }
            
            .drug-name {
                font-size: 24px;
            }
            
            .stats-grid {
                grid-template-columns: 1fr 1fr;
            }
            
            .dosing-grid {
                grid-template-columns: 1fr;
            }
            
            .nav-tabs {
                overflow-x: auto;
            }
        }
    </style>
</head>
<body>
    <header class="header">
        <div class="header-content">
            <a href="index.html" class="back-button">
                ‚Üê Back to Dashboard
            </a>
            <div class="status-badge">NMPA APPROVED 2024</div>
        </div>
    </header>

    <div class="container">
        <!-- Hero Section -->
        <div class="hero-section">
            <div class="drug-title">
                <h1 class="drug-name">Ebronucimab (AK102)</h1>
                <div class="drug-company">Akeso Inc. ‚Ä¢ China</div>
                <div class="drug-mechanism">PCSK9 Monoclonal Antibody</div>
            </div>
            
            <div class="stats-grid">
                <div class="stat-card">
                    <div class="stat-value">65%</div>
                    <div class="stat-label">Max LDL Reduction</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">Q6W</div>
                    <div class="stat-label">Best Dosing Option</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">8-9</div>
                    <div class="stat-label">Injections/Year (Q6W)</div>
                </div>
                <div class="stat-card">
                    <div class="stat-value">China Only</div>
                    <div class="stat-label">Current Availability</div>
                </div>
            </div>
        </div>

        <!-- Navigation Tabs -->
        <div class="nav-tabs">
            <button class="nav-tab active" onclick="showTab('overview')">Overview</button>
            <button class="nav-tab" onclick="showTab('clinical')">Clinical Data</button>
            <button class="nav-tab" onclick="showTab('regulatory')">Regulatory</button>
            <button class="nav-tab" onclick="showTab('safety')">Safety</button>
            <button class="nav-tab" onclick="showTab('commercial')">Commercial</button>
        </div>

        <!-- Overview Tab -->
        <div id="overview" class="tab-content active">
            <div class="section">
                <h2 class="section-header">Key Information</h2>
                
                <div class="info-card">
                    <h3>Mechanism of Action</h3>
                    <p>Fully human IgG1 monoclonal antibody that binds circulating PCSK9, preventing LDL receptor degradation. This leads to:</p>
                    <ul>
                        <li>Increased hepatic LDL receptor expression</li>
                        <li>Enhanced LDL-C clearance from circulation</li>
                        <li>50-70% LDL-C reduction within 1-2 weeks</li>
                        <li>Minimal impact on triglycerides or HDL-C</li>
                    </ul>
                </div>

                <div class="info-card">
                    <h3>Target Population</h3>
                    <p>Adults with primary hypercholesterolemia (including HeFH) and mixed dyslipidemia who:</p>
                    <ul>
                        <li>Are on maximally tolerated statin therapy</li>
                        <li>Are statin-intolerant</li>
                        <li>Require additional LDL-C reduction beyond current therapy</li>
                    </ul>
                </div>

                <h3 style="margin-top: 24px; margin-bottom: 16px; font-size: 16px; color: var(--text-primary);">Dosing Regimens</h3>
                <div class="dosing-grid">
                    <div class="dosing-card">
                        <div class="dosing-frequency">Q2W</div>
                        <div class="dosing-details">
                            <strong>150 mg</strong>
                            Every 2 weeks<br>
                            26 injections/year<br>
                            65% LDL reduction
                        </div>
                    </div>
                    <div class="dosing-card">
                        <div class="dosing-frequency">Q4W</div>
                        <div class="dosing-details">
                            <strong>300-450 mg</strong>
                            Monthly<br>
                            12 injections/year<br>
                            66% LDL reduction
                        </div>
                    </div>
                    <div class="dosing-card featured">
                        <div class="dosing-frequency">Q6W ‚≠ê</div>
                        <div class="dosing-details">
                            <strong>420-450 mg</strong>
                            Every 6 weeks<br>
                            8-9 injections/year<br>
                            60% LDL reduction<br>
                            <em style="color: var(--primary);">Key differentiator</em>
                        </div>
                    </div>
                </div>

                <div class="alert alert-info" style="margin-top: 24px;">
                    <span class="alert-icon">üí°</span>
                    <div class="alert-content">
                        <strong>Competitive Positioning:</strong> Q6W dosing offers better convenience than biweekly mAbs (26 injections/year) but still requires more injections than inclisiran (2/year). Success depends on aggressive pricing and securing reimbursement through China's NRDL.
                    </div>
                </div>
            </div>
        </div>

        <!-- Clinical Data Tab -->
        <div id="clinical" class="tab-content">
            <div class="section">
                <h2 class="section-header">Clinical Trials Overview</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Trial</th>
                            <th>Phase</th>
                            <th>N</th>
                            <th>Population</th>
                            <th>Duration</th>
                            <th>Primary Endpoint</th>
                            <th>Key Results</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>Dose Escalation</strong></td>
                            <td>I</td>
                            <td>~100</td>
                            <td>Healthy volunteers</td>
                            <td>8 weeks</td>
                            <td>Safety/PK/PD</td>
                            <td>LDL ‚Üì70% (single dose)</td>
                        </tr>
                        <tr>
                            <td><strong>AK102-301</strong></td>
                            <td>III</td>
                            <td>480</td>
                            <td>Primary HC/Mixed</td>
                            <td>52 weeks</td>
                            <td>% LDL change at wk 12</td>
                            <td>65-66% reduction</td>
                        </tr>
                        <tr>
                            <td><strong>AK102-302</strong></td>
                            <td>III</td>
                            <td>264</td>
                            <td>HeFH</td>
                            <td>12 weeks</td>
                            <td>% LDL change at wk 12</td>
                            <td>60-65% reduction</td>
                        </tr>
                        <tr>
                            <td><strong>AK102-303</strong></td>
                            <td>III</td>
                            <td>360</td>
                            <td>Primary HC (Q6W)</td>
                            <td>12 weeks</td>
                            <td>% LDL change at wk 12</td>
                            <td>60% reduction (Q6W)</td>
                        </tr>
                        <tr>
                            <td><strong>AK102-304</strong></td>
                            <td>III</td>
                            <td>240</td>
                            <td>High-risk HC</td>
                            <td>12 weeks</td>
                            <td>% LDL reduction</td>
                            <td>~65% reduction</td>
                        </tr>
                    </tbody>
                </table>

                <div class="alert alert-warning" style="margin-top: 20px;">
                    <span class="alert-icon">‚ö†Ô∏è</span>
                    <div class="alert-content">
                        <strong>No CV Outcomes Data:</strong> All trials used LDL-C as surrogate endpoint. No MACE reduction studies completed or ongoing. Approval based on biomarker efficacy similar to initial PCSK9 mAb approvals.
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Efficacy Profile</h2>
                
                <div class="efficacy-chart">
                    <h3 style="font-size: 14px; margin-bottom: 16px;">LDL-C Reduction by Dosing Regimen</h3>
                    <div class="chart-container">
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">65%</div>
                            <div class="chart-bar" style="height: 65%;"></div>
                            <div class="chart-label">Q2W<br>150mg</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">66%</div>
                            <div class="chart-bar" style="height: 66%;"></div>
                            <div class="chart-label">Q4W<br>450mg</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">60%</div>
                            <div class="chart-bar" style="height: 60%;"></div>
                            <div class="chart-label">Q6W<br>420mg</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">50%</div>
                            <div class="chart-bar secondary" style="height: 50%;"></div>
                            <div class="chart-label">ApoB<br>Reduction</div>
                        </div>
                        <div class="chart-bar-wrapper">
                            <div class="chart-value">80-90%</div>
                            <div class="chart-bar success" style="height: 85%;"></div>
                            <div class="chart-label">Achieved<br>&lt;70 mg/dL</div>
                        </div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 20px;">
                    <h3>Key Efficacy Points</h3>
                    <ul>
                        <li>Consistent 60-66% LDL reduction across all dosing regimens</li>
                        <li>80-90% of patients achieved guideline LDL goals (&lt;70 mg/dL)</li>
                        <li>Sustained efficacy over 52 weeks in long-term extension</li>
                        <li>Q6W dosing maintains smooth LDL control without trough spikes</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Regulatory Tab -->
        <div id="regulatory" class="tab-content">
            <div class="section">
                <h2 class="section-header">Regulatory Timeline</h2>
                
                <div class="timeline">
                    <div class="timeline-line"></div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">November 2018</div>
                            <div class="timeline-title">Phase I Completion</div>
                            <div class="timeline-description">Safety and PK/PD established, up to 70% LDL reduction with single dose</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">December 2021</div>
                            <div class="timeline-title">Phase III Enrollment Complete</div>
                            <div class="timeline-description">All four pivotal trials fully enrolled</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">May 2023</div>
                            <div class="timeline-title">Phase III Results Announced</div>
                            <div class="timeline-description">60-66% LDL reduction demonstrated across regimens</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">June 2, 2023</div>
                            <div class="timeline-title">NDA Accepted by NMPA</div>
                            <div class="timeline-description">Application for hypercholesterolemia accepted for review</div>
                        </div>
                    </div>
                    
                    <div class="timeline-item complete">
                        <div class="timeline-dot"></div>
                        <div class="timeline-content">
                            <div class="timeline-date">September 30, 2024</div>
                            <div class="timeline-title"><strong>APPROVAL GRANTED</strong></div>
                            <div class="timeline-description">Approved based on four Phase III trials. Trade name: ‰ºäÂñúÂÆÅ (Yixining)</div>
                        </div>
                    </div>
                </div>

                <div class="alert alert-warning">
                    <span class="alert-icon">‚ö†Ô∏è</span>
                    <div class="alert-content">
                        <strong>International Status:</strong> No FDA or EMA filings as of 2025. Global expansion would require bridging studies in diverse populations and GMP inspections of Chinese manufacturing sites. Potential Western partnership could accelerate international development.
                    </div>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Regulatory Comparison</h2>
                
                <table class="data-table">
                    <thead>
                        <tr>
                            <th>Region</th>
                            <th>Status</th>
                            <th>Filing Date</th>
                            <th>Approval Date</th>
                            <th>Notes</th>
                        </tr>
                    </thead>
                    <tbody>
                        <tr>
                            <td><strong>China (NMPA)</strong></td>
                            <td><span class="badge badge-success">Approved</span></td>
                            <td>June 2023</td>
                            <td>Sept 2024</td>
                            <td>15-month review, no issues</td>
                        </tr>
                        <tr>
                            <td><strong>United States (FDA)</strong></td>
                            <td><span class="badge badge-warning">Not Filed</span></td>
                            <td>‚Äî</td>
                            <td>‚Äî</td>
                            <td>Would need bridging studies</td>
                        </tr>
                        <tr>
                            <td><strong>Europe (EMA)</strong></td>
                            <td><span class="badge badge-warning">Not Filed</span></td>
                            <td>‚Äî</td>
                            <td>‚Äî</td>
                            <td>Potential Menarini partnership</td>
                        </tr>
                        <tr>
                            <td><strong>Japan (PMDA)</strong></td>
                            <td><span class="badge badge-warning">Not Filed</span></td>
                            <td>‚Äî</td>
                            <td>‚Äî</td>
                            <td>No current plans</td>
                        </tr>
                    </tbody>
                </table>
            </div>
        </div>

        <!-- Safety Tab -->
        <div id="safety" class="tab-content">
            <div class="section">
                <h2 class="section-header">Safety Profile</h2>
                
                <p style="margin-bottom: 20px; font-size: 14px;">Cumulative exposure: ~2,000 patient-years by 2025. No black-box warnings.</p>
                
                <div class="safety-grid">
                    <div class="safety-item">
                        <div class="safety-value">70-80%</div>
                        <div class="safety-label">Overall AEs (similar to placebo)</div>
                    </div>
                    <div class="safety-item">
                        <div class="safety-value">5-10%</div>
                        <div class="safety-label">Serious AEs</div>
                    </div>
                    <div class="safety-item">
                        <div class="safety-value">&lt;2%</div>
                        <div class="safety-label">Discontinuation due to AEs</div>
                    </div>
                    <div class="safety-item">
                        <div class="safety-value">5-10%</div>
                        <div class="safety-label">Injection site reactions</div>
                    </div>
                    <div class="safety-item">
                        <div class="safety-value">8-12%</div>
                        <div class="safety-label">Nasopharyngitis</div>
                    </div>
                    <div class="safety-item">
                        <div class="safety-value">1-3%</div>
                        <div class="safety-label">Anti-drug antibodies</div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 24px;">
                    <h3>Neurocognitive Safety</h3>
                    <p>No signals in trials despite 20-30% achieving very low LDL (&lt;25 mg/dL). Memory impairment and confusion &lt;1%, similar to placebo. Consistent with PCSK9 class data showing no cognitive decline even at LDL &lt;15 mg/dL over 5+ years.</p>
                </div>

                <div class="info-card">
                    <h3>Immunogenicity</h3>
                    <p>As a fully human monoclonal antibody, immunogenic potential is low. Anti-drug antibodies detected in 1-3% of patients with no impact on efficacy or safety. No neutralizing antibodies reported.</p>
                </div>

                <div class="info-card">
                    <h3>Special Populations</h3>
                    <ul>
                        <li><strong>Elderly:</strong> No dose adjustment needed, similar safety profile</li>
                        <li><strong>Renal impairment:</strong> No dose adjustment (mAbs not renally cleared)</li>
                        <li><strong>Hepatic impairment:</strong> Limited data, use with caution</li>
                        <li><strong>Pregnancy:</strong> Category B equivalent (animal studies negative)</li>
                    </ul>
                </div>
            </div>
        </div>

        <!-- Commercial Tab -->
        <div id="commercial" class="tab-content">
            <div class="section">
                <h2 class="section-header">Market Position</h2>
                
                <div class="stats-grid">
                    <div class="stat-card">
                        <div class="stat-value">¬•8-12K</div>
                        <div class="stat-label">Expected Annual Cost</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">30-50%</div>
                        <div class="stat-label">Below Import Price</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">Pending</div>
                        <div class="stat-label">NRDL Status</div>
                    </div>
                    <div class="stat-card">
                        <div class="stat-value">10-20%</div>
                        <div class="stat-label">Est. First Year Uptake</div>
                    </div>
                </div>

                <div class="info-card" style="margin-top: 24px;">
                    <h3>Pricing Strategy</h3>
                    <p>Expected ¬•8,000-12,000/year (approximately $1,100-1,650 USD), positioning 30-50% below imported PCSK9 mAbs like Repatha. Final pricing pending NRDL negotiations.</p>
                </div>

                <div class="info-card">
                    <h3>Reimbursement Outlook</h3>
                    <p>Not yet on National Reimbursement Drug List (NRDL). Inclusion in 2025-2026 cycles could provide 70-80% coverage, dramatically improving access. Government CV disease initiatives favor domestic products.</p>
                    <div class="progress-bar">
                        <div class="progress-fill" style="width: 10%;"></div>
                    </div>
                    <small style="color: var(--text-secondary);">Current reimbursement coverage: ~10%</small>
                </div>

                <div class="info-card">
                    <h3>Competitive Advantages</h3>
                    <ul>
                        <li>Q6W dosing offers improved convenience (8-9 injections/year)</li>
                        <li>Domestic production avoids import costs and supply chain issues</li>
                        <li>Government "Healthy China 2030" initiative supports local innovation</li>
                        <li>First domestic PCSK9 mAb in large Chinese market</li>
                    </ul>
                </div>

                <div class="info-card">
                    <h3>Market Challenges</h3>
                    <ul>
                        <li>Inclisiran entering China with 2x/year dosing advantage</li>
                        <li>Oral PCSK9 inhibitors coming by 2026-2027</li>
                        <li>No CV outcomes data vs proven benefit for Repatha/Praluent</li>
                        <li>Limited global expansion potential without partner</li>
                    </ul>
                </div>
            </div>

            <div class="section">
                <h2 class="section-header">Future Outlook</h2>
                
                <div class="info-card">
                    <h3>Near-term (2025-2027)</h3>
                    <ul>
                        <li>Focus on NRDL inclusion for broader reimbursement</li>
                        <li>Real-world evidence collection in Chinese population</li>
                        <li>Potential partnership discussions for global development</li>
                        <li>Competition from inclisiran China launch</li>
                    </ul>
                </div>

                <div class="info-card">
                    <h3>Long-term (2028-2030)</h3>
                    <ul>
                        <li>Biosimilar competition from Repatha/Praluent</li>
                        <li>Oral PCSK9 inhibitors may dominate new prescriptions</li>
                        <li>May become niche option for specific populations</li>
                        <li>Potential EMA/FDA filing if partnered with Western company</li>
                    </ul>
                </div>

                <div class="alert alert-info" style="margin-top: 24px;">
                    <span class="alert-icon">üéØ</span>
                    <div class="alert-content">
                        <strong>Strategic Summary:</strong> Ebronucimab's success depends on aggressive pricing, securing NRDL inclusion, and leveraging Q6W dosing convenience. Without CV outcomes data or global presence, it faces challenges from inclisiran's superior dosing and upcoming oral alternatives. Best positioned as China's domestic champion in the near term.
                    </div>
                </div>
            </div>
        </div>
    </div>

    <script>
        function showTab(tabName) {
            // Hide all tabs
            const tabs = document.querySelectorAll('.tab-content');
            tabs.forEach(tab => tab.classList.remove('active'));
            
            // Remove active from all nav tabs
            const navTabs = document.querySelectorAll('.nav-tab');
            navTabs.forEach(tab => tab.classList.remove('active'));
            
            // Show selected tab
            document.getElementById(tabName).classList.add('active');
            
            // Mark nav tab as active
            event.target.classList.add('active');
        }
        
        // Animate progress bars and charts on scroll
        const observer = new IntersectionObserver((entries) => {
            entries.forEach(entry => {
                if (entry.isIntersecting) {
                    // Animate progress bars
                    const progressFills = entry.target.querySelectorAll('.progress-fill');
                    progressFills.forEach(fill => {
                        const width = fill.style.width;
                        fill.style.width = '0';
                        setTimeout(() => {
                            fill.style.width = width;
                        }, 100);
                    });
                    
                    // Animate chart bars
                    const chartBars = entry.target.querySelectorAll('.chart-bar');
                    chartBars.forEach((bar, index) => {
                        const height = bar.style.height;
                        bar.style.height = '0';
                        setTimeout(() => {
                            bar.style.height = height;
                        }, index * 100);
                    });
                    
                    observer.unobserve(entry.target);
                }
            });
        }, { threshold: 0.1 });
        
        // Observe all sections
        document.querySelectorAll('.section').forEach(section => {
            observer.observe(section);
        });
    </script>
</body>
</html>